Browse News
Filter News
Found 150 articles
-
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
1/8/2023
Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
12/5/2022
Protalix BioTherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease.
-
Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention
12/2/2022
Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group, announced its sponsorship of the ASHP Advantage initiative to support pharmacy technician recruitment and retention.
-
Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome
11/29/2022
Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group, announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
11/14/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced the resubmission on November 9, 2022 of a Biologics License Application to the U.S. Food and Drug Administration for PRX–102 for the treatment of adult patients with Fabry disease.
-
While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.
-
Aptar and Chiesi Sign Digital Health Contract to bring Best-in-Class Disease Management Platform for Patients with Asthma and COPD
10/18/2022
Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic partnership with the Chiesi Group, the international research-focused biopharmaceutical and healthcare group, to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease (COPD).
-
Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals
10/17/2022
Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, has been ranked No. 15 among Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals.
-
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size to Surpass US$ 31.4 BN By 2030
9/29/2022
According to latest report study, the global Chronic Obstructive Pulmonary Disease (COPD) Treatment market size was estimated at USD 19.11 billion in 2021 and is expected to surpass around USD 31.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period 2022 to 2030.
-
XNK Therapeutics appoints Dr. Anna-Karin Maltais as CSO
9/15/2022
XNK Therapeutics AB announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer, effective October 17th.
-
Chiesi Global Rare Diseases Announces FDA Acceptance of BLA Filing for Velmanase Alfa for the Proposed Treatment of Alpha-Mannosidosis
9/12/2022
Chiesi Global Rare Diseases announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for velmanase alfa, the company's investigational enzyme replacement therapy for the proposed treatment of alpha-mannosidosis.
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Chiesi Global Rare Diseases Announces Presentations on Lysosomal Storage Diseases at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
9/2/2022
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced multiple presentations focused on the research and treatment of lysosomal storage diseases (LSDs) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium being held in Freiburg, Germany 30 August – 2 September, 2022.
-
iZafe Signs a Letter of Intent to Acquire Pilloxa AB
8/18/2022
iZafe Group AB has signed a Letter of Intent with Pilloxa AB regarding the acquisition of 100 percent of the shares in Pilloxa.
-
Respiratory Virus Infection Drugs Market Size | USD 82.1 Billion by 2030
8/2/2022
According to latest report, the global respiratory virus infection drugs market size valued at US$ 38.8 billion in 2020 and is predicted to hit around US$ 82.1 billion by 2030, expanding at a CAGR of 7.1% from 2021 to 2030.
-
Alpha Mannosidosis Market: Key Trends & Competitive Landscape
7/20/2022
According to Transparency Market Research’s latest report on the global alpha mannosidosis market for the historical period 2017–2018 and forecast period 2019–2027, market exclusivity for orphan drugs, increasing investment in rare disease treatment, and faster market access are projected to drive the global alpha mannosidosis market during the forecast period.
-
Chiesi tracks actions taken for a healthier, more sustainable future
7/14/2022
Chiesi, the international research-focused biopharmaceutical group, released its Annual and Sustainability Report for 2021.
-
Respiratory Virus Infection Drugs Market Size to Hit US$ 82.1 Billion by 2030
7/12/2022
According to latest report study, the global respiratory virus infection drugs market reached value at US$ 38.8 Bn in 2020 and predicted to hit around US$ 82.1 billion by 2030, expanding at a CAGR of 7.1% from 2021 to 2030.
-
Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference
6/9/2022
Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne muscular dystrophy.
-
Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice
6/1/2022
Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced its first full analysis publication from the CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry that evaluated KENGREAL® (cangrelor) use and transition to oral P2Y12 inhibitors in routine clinical practice.